Key result
Low-molecular-weight heparin did not significantly improve livebirth rates compared with no LMWH in women with inherited thrombophilia and prior pregnancy loss (RR 0.81; 95% CI 0.55-1.19; P=.28).
Why the study?
Does low-molecular-weight heparin improve livebirth rates in women with inherited thrombophilia and prior pregnancy loss?
Meta-Analysis (n=483)
Does low-molecular-weight heparin improve livebirth rates in women with inherited thrombophilia and prior pregnancy loss?
Relative Risk: 0.81 (95% CI 0.55–1.19)
p-value: p=.28
Low-molecular-weight heparin does not provide a benefit in preventing recurrent pregnancy loss or improving livebirth rates in women with inherited thrombophilia.
LMWH should not be used to improve livebirth rates in this setting; confirms no benefit and should inform guideline revisions.
We performed a meta-analysis of randomized controlled trials comparing low-molecular-weight heparin (LMWH) vs no LMWH in women with inherited thrombophilia and prior late (≥10 weeks) or recurrent early (<10 weeks) pregnancy loss. Eight trials and 483 patients met our inclusion criteria. There was no significant difference in livebirth rates with the use of LMWH compared with no LMWH (relative risk, 0.81; 95% confidence interval, 0.55-1.19;P= .28), suggesting no benefit of LMWH in preventing recurrent pregnancy loss in women with inherited thrombophilia.
No takes yet. Share an insight, caveat, or question.
Skeith et al. (2016) conducted a meta-analysis in Inherited thrombophilia and prior pregnancy loss (n=483). Low-molecular-weight heparin (LMWH) vs. No LMWH was evaluated on Livebirth rates (RR 0.81, 95% CI 0.55-1.19, p=.28). Low-molecular-weight heparin did not significantly improve livebirth rates compared with no LMWH in women with inherited thrombophilia and prior pregnancy loss (RR 0.81; 95% CI 0.55-1.19; P=.28).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: